ABBV-085 is a novel antibody–drug conjugate (ADC) that targets LRRC15 in the tumor microenvironment. (December 2016) - Purcell, J.; Hickson, J.; Tanlimco, S.; Fox, M.; Chao, D.; Hsi, E.; Sho, M.; Powers, R.; Foster-Duke, K.; McGonigal, T.; Uziel, T.; Kumar, S.; et al.